Literature DB >> 8887630

Transcriptional activation of the human epidermal growth factor receptor promoter by human p53.

J H Ludes-Meyers1, M A Subler, C V Shivakumar, R M Munoz, P Jiang, J E Bigger, D R Brown, S P Deb, S Deb.   

Abstract

The human epidermal growth factor receptor (EGFR) promoter is activated by both wild-type and tumor-derived mutant p53. In this communication, we demonstrate that EGFR promoter sequence requirements for transactivation by wild-type and mutant p53 are different. Transient-expression assays with EGFR promoter deletions identified a wild-type human p53 response element, 5'-AGCTAGACGTCCGGGCAGCCCCCGGCG -3', from positions --265 to --239. Electrophoretic mobility shift analysis and DNase I footprinting assays indicated that wild-type p53 binds sequence specifically to the response element. Using circularly permuted DNA fragments containing the p53-binding site, we show that wild-type p53 binding induces DNA bending at this site. We further show that the EGFR promoter is also activated by tumor-derived p53 mutants p53-143A, p53-175H, p53-248W, p53-273H, and p53-281G. However, the transactivation by mutant p53 does not require the wild-type p53-binding site. The minimal EGFR promoter from positions --104 to --20 which does not contain the wild-type p53-binding site is transactivated by the p53 mutants but not by the wild-type protein, showing a difference in the mechanism of transactivation by wild-type and mutant p53. Transactivation of the EGFR promoter by p53 may represent a novel mechanism of cell growth regulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887630      PMCID: PMC231603          DOI: 10.1128/MCB.16.11.6009

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  123 in total

Review 1.  Transcriptional repression of eukaryotic promoters.

Authors:  M Levine; J L Manley
Journal:  Cell       Date:  1989-11-03       Impact factor: 41.582

Review 2.  How eukaryotic transcriptional activators work.

Authors:  M Ptashne
Journal:  Nature       Date:  1988-10-20       Impact factor: 49.962

Review 3.  Action at a distance along a DNA.

Authors:  J C Wang; G N Giaever
Journal:  Science       Date:  1988-04-15       Impact factor: 47.728

4.  Epidermal growth factor receptor gene promoter. Deletion analysis and identification of nuclear protein binding sites.

Authors:  A C Johnson; S Ishii; Y Jinno; I Pastan; G T Merlino
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

5.  Empirical estimation of protein-induced DNA bending angles: applications to lambda site-specific recombination complexes.

Authors:  J F Thompson; A Landy
Journal:  Nucleic Acids Res       Date:  1988-10-25       Impact factor: 16.971

6.  A new class of yeast transcriptional activators.

Authors:  J Ma; M Ptashne
Journal:  Cell       Date:  1987-10-09       Impact factor: 41.582

7.  The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription.

Authors:  J Haley; N Whittle; P Bennet; D Kinchington; A Ullrich; M Waterfield
Journal:  Oncogene Res       Date:  1987 Sep-Oct

8.  Molecular cloning and characterization of a human DNA binding factor that represses transcription.

Authors:  R Kageyama; I Pastan
Journal:  Cell       Date:  1989-12-01       Impact factor: 41.582

9.  Epidermal growth factor (EGF) receptor gene transcription. Requirement for Sp1 and an EGF receptor-specific factor.

Authors:  R Kageyama; G T Merlino; I Pastan
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

10.  Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene.

Authors:  T J Velu; L Beguinot; W C Vass; M C Willingham; G T Merlino; I Pastan; D R Lowy
Journal:  Science       Date:  1987-12-04       Impact factor: 47.728

View more
  57 in total

1.  PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway.

Authors:  M Tan; Y Wang; K Guan; Y Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 3.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

4.  Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter.

Authors:  J Bian; Y Sun
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

5.  Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators.

Authors:  Jamie M Hearnes; Deborah J Mays; Kristy L Schavolt; Luojia Tang; Xin Jiang; Jennifer A Pietenpol
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

6.  Pleiotropic Role of p53 in Injury and Liver Regeneration after Acetaminophen Overdose.

Authors:  Prachi Borude; Bharat Bhushan; Sumedha Gunewardena; Jephte Akakpo; Hartmut Jaeschke; Udayan Apte
Journal:  Am J Pathol       Date:  2018-04-11       Impact factor: 4.307

7.  p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

Authors:  C J Di Como; C Gaiddon; C Prives
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

8.  Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.

Authors:  Heidi Sankala; Catherine Vaughan; Jing Wang; Sumitra Deb; Paul R Graves
Journal:  Arch Biochem Biophys       Date:  2011-05-20       Impact factor: 4.013

Review 9.  Crosstalk of Notch with p53 and p63 in cancer growth control.

Authors:  G Paolo Dotto
Journal:  Nat Rev Cancer       Date:  2009-07-16       Impact factor: 60.716

10.  Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells.

Authors:  L Sauer; D Gitenay; C Vo; V T Baron
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.